PT-141 Peptide Nasal Spray

Description

PT-141 Nasal Spray (Bremelanotide): How to Use PT-141 Nasal Spray & PT 141 Nasal Spray for Women — Research Guide

Buy PT-141 Nasal Spray (Bremelanotide) 10mg — Premium Intranasal Peptide Delivery

Looking to buy PT-141 nasal spray for advanced melanocortin receptor research? PrymaLab offers research-grade PT-141 peptide nasal spray (bremelanotide) with verified 99%+ purity via independent HPLC analysis. Our intranasal form delivers 10mg of bremelanotide in a ready-to-use, pre-calibrated metered spray — eliminating the need for mixing, syringes, or subcutaneous injection. Each spray provides a consistent, pre-measured dose for standardized research protocols.

What Is PT-141 (Bremelanotide)?

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide consisting of seven amino acids that functions as a melanocortin receptor agonist, mainly targeting the MC4R and MC1R receptors in the central nervous system. Originally derived from the alpha-melanocyte-stimulating hormone (α-MSH) analog Melanotan II, PT-141 has been the subject of extensive clinical and lab research for its role in modulating sexual function through central nervous system pathways rather than peripheral vascular mechanisms.
Unlike PDE5 inhibitors such as tadalafil or sildenafil that act on blood flow, PT-141 works through a fundamentally different pathway. Research shows it increases dopaminergic activity in the medial preoptic area of the hypothalamus by activating melanocortin-4 receptors (MC4R) and melanocortin-3 receptors (MC3R). This mechanism was confirmed through multiple Phase II and Phase III clinical trials that led to FDA approval of bremelanotide (brand name Vyleesi) in June 2019 for treating hypoactive sexual desire disorder (HSDD) — a recognized form of female sexual dysfunction — in premenopausal women.
Our PT-141 peptide nasal spray delivers 10mg of research-grade bremelanotide via intranasal administration. Each spray delivers a consistent, pre-measured dose, making it significantly more practical for standardized research protocols. The current batch (PH-2026-NS087) tests at 99.4% purity via independent HPLC analysis, with full mass spectrometry confirmation of correct molecular identity.
Research Summary: PT-141 (CAS: 189691-06-3) is a cyclic 7-amino-acid peptide with a half-life of 2.7 hours and 100% subcutaneous bioavailability. It acts as an agonist at MC4R, MC1R, MC3R, MC5R, and MC2R melanocortin receptors. Over 10 published clinical trials and multiple FDA reviews have documented its pharmacological profile.

Key Features & Specifications

Complete technical data for PT-141 (bremelanotide) 10mg nasal spray:

PT-141 Benefits for Research

The research interest in PT-141 spans multiple domains, driven by its unique mechanism of action that targets central nervous system melanocortin receptors rather than peripheral vascular pathways. This central mechanism makes it a valuable tool for researchers studying the neurobiology of sexual function, melanocortin signaling, and dopaminergic pathways.

Breakthrough Research Applications

• Sexual Function Research — PT-141 is the only FDA-reviewed compound that modulates sexual function through central melanocortin pathways rather than peripheral vasodilation, making it uniquely valuable for neurobiology and sexual dysfunction research.
• Melanocortin Receptor Studies — As an agonist at five melanocortin receptor subtypes (MC1R–MC5R), bremelanotide provides researchers with a versatile pharmacological tool for studying the melanocortin system.
• Dopaminergic Pathway Research — Published data shows PT-141 increases dopaminergic activity in the medial preoptic area, enabling studies on dopamine’s role in motivated behavior.
• Intranasal Peptide Delivery — The nasal spray format enables research into mucosal peptide absorption, nose-to-brain transport, and non-invasive CNS-targeted delivery systems.
• Comparative Pharmacology — Researchers use PT-141 alongside PDE5 inhibitors and other sexual function compounds to compare central vs. peripheral mechanisms of action.

Why Choose Our PT-141 Nasal Spray?

Every batch of our PT-141 nasal spray is tested by an independent, ISO 17025-accredited laboratory — not just by in-house quality control. You get a batch-specific Certificate of Analysis (COA) showing exact purity percentages, impurity profiles, and molecular identity confirmation via mass spectrometry. Our current batch tests at 99.4% purity via HPLC, with full MS confirmation of the correct 1025.18 g/mol molecular weight.
Unlike freeze-dried PT-141 powder that needs mixing with sterile water, our nasal spray format is ready to use out of the box. Each actuation delivers a consistent, calibrated dose — eliminating variability from manual mixing and syringe measurement. The spray mechanism was tested for 50+ actuations to ensure consistent volume delivery (coefficient of variation <5%).

• ✓ No Mixing Needed — Ready-to-use nasal spray eliminates the need for sterile water, sterile syringes, and manual dose calculation. Simply prime and administer.
• ✓ 99.4% HPLC Purity — Current batch PH-2026-NS087 independently verified at 99.4% purity. Dual-verified via HPLC separation analysis and mass spectrometry identity confirmation.
• ✓ Calibrated Metered Dosing — Each spray delivers a precisely calibrated dose with <5% coefficient of variation across 50+ actuations. Standardize your research protocols with confidence.
• ✓ 12-Month Shelf Life — Formulated in a stabilizing solution that maintains peptide integrity for 12 months at 2–8°C. No freeze-thaw cycles needed, unlike freeze-dried alternatives.

PT-141 Nasal Spray vs Injection: Key Differences

Researchers often compare the nasal spray and subcutaneous injection delivery methods for PT-141 (bremelanotide). Both approaches have distinct benefits depending on your research design, and understanding these differences helps optimize your experimental protocols.

The nasal spray delivery route has gained significant research attention because intranasal peptide delivery can bypass first-pass metabolism and offers direct access to the central nervous system via the olfactory and trigeminal nerve pathways. For researchers prioritizing convenience, dosing consistency, and reduced contamination risk, the PT-141 nasal spray offers clear practical benefits. For studies needing confirmed 100% bioavailability, subcutaneous injection remains the gold-standard route documented in published pharmacokinetic literature.

How to Use PT-141 Nasal Spray for Research

Proper administration technique ensures consistent dosing across research protocols. Follow these steps for optimal results with the PT-141 peptide nasal spray:

Step 1: Remove from Refrigerated Storage

Allow the nasal spray bottle to reach room temperature (about 10–15 minutes). Do not heat or microwave. Verify the seal is intact before first use.

Step 2: Prime the Spray Mechanism (First Use Only)

Remove the cap and hold the bottle upright. Press the actuator 3–4 times until a fine mist appears. This primes the pump and ensures the first research dose is accurately metered. Re-priming is needed if unused for more than 7 days.

Step 3: Administer the Dose

Insert the spray tip into the nostril. Press the actuator firmly once for a single metered dose. Each actuation delivers about 333mcg of PT-141 (bremelanotide). For alternate-nostril protocols, administer the next spray in the opposite nostril.

Step 4: Record the Dose and Time

Document the number of sprays, nostril used, and exact time of administration in your research log. Consistent record-keeping is essential for reproducible results.

Step 5: Return to Refrigerated Storage

Replace the cap and return the bottle to 2–8°C storage immediately after use. Avoid leaving at room temperature for extended periods. The spray remains stable for 12 months when stored properly.
Important Research Note: Published clinical trial data for bremelanotide used subcutaneous injection at 1.75mg per dose. PT-141 dosage protocols for intranasal research should be determined based on your specific study design and institutional guidelines. This product is sold for research purposes only.

PT-141 Dosage Guide for Research

Understanding PT-141 dosage parameters is essential for designing effective research protocols. The following data is compiled from published clinical trial results and FDA-reviewed pharmacokinetic studies.

Dosage Note for Researchers: All dosage data presented here is derived from published, peer-reviewed clinical trial data and FDA-approved labeling. Specific PT-141 dosage for your research protocols should be determined by your principal investigator based on your study objectives, model system, and institutional approval.

Storage & Handling Instructions

Store the PT-141 nasal spray at 2–8°C (standard refrigerator temperature) for maximum shelf life. The sealed spray mechanism protects the peptide solution from contamination and oxidation, providing a 12-month shelf life when stored properly. Keep the bottle away from direct light and do not freeze. Unlike freeze-dried PT-141 powder that needs -20°C storage and careful mixing, the nasal spray format is ready to use directly from the refrigerator — simply allow 10–15 minutes to reach room temperature before use.

• ✓ Storage Temperature: 2–8°C (standard refrigerator)
• ✓ Shelf Life: 12 months when stored properly
• ✓ Sprays per Bottle: About 30 metered actuations
• ✓ Dose Variation: <5% coefficient of variation across all actuations

Frequently Asked Questions About PT-141 Nasal Spray

How long does PT-141 last?

PT-141 (bremelanotide) has a plasma half-life of about 2.7 hours (range 1.9–4.0 hours) based on published pharmacokinetic data from the FDA-approved label. Peak plasma level (Tmax) is reached within 1 hour (about 60 minutes) of administration, and in published clinical research onset of effects was typically observed within 30 to 60 minutes. Research protocols often observe effects within a 6–8 hour window following dosing, though the compound is largely cleared from plasma within 12 hours.

What are the side effects of PT-141 nasal spray?

In clinical research trials reviewed by the FDA, the most common side effect of PT-141 (bremelanotide) is nausea (reported in about 40% of clinical trial participants); other common side effects include headache, facial flushing, and injection-site reactions. The nasal spray delivery format may also cause temporary nasal congestion or mild nasal irritation. Transient, non-clinically-significant increases in blood pressure have also been documented. MC1R agonism may cause focal hyperpigmentation with repeated use.

PT-141 nasal spray vs injection — which is better for research?

Both delivery methods offer distinct benefits depending on research objectives. The nasal spray provides faster administration, eliminates the need for mixing with sterile water, and delivers consistent pre-measured dosing with less contamination risk. Subcutaneous injection achieves documented 100% bioavailability per FDA pharmacokinetic data. For standardized, high-throughput protocols where convenience and dosing consistency are priorities, nasal spray is often preferred. For pharmacokinetic studies requiring confirmed bioavailability, injection remains the published reference standard.

Does PT-141 increase testosterone?

PT-141 (bremelanotide) does not directly increase testosterone levels. Its mechanism of action operates through melanocortin receptor activation in the central nervous system — mainly MC4R and MC3R receptors — which modulate dopaminergic signaling in the medial preoptic area of the hypothalamus. This pathway is independent of the hypothalamic-pituitary-gonadal (HPG) axis that regulates testosterone production. PT-141 should not be confused with SARMs or testosterone-modulating compounds.

What does PT-141 do?

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide that acts as a melanocortin receptor agonist. It mainly targets MC4R and MC1R receptors in the central nervous system. Published research shows it modulates sexual function pathways by increasing dopaminergic activity in the medial preoptic area, rather than through peripheral vascular mechanisms like PDE5 inhibitors. It received FDA approval in June 2019 under the brand name Vyleesi for treating hypoactive sexual desire disorder (HSDD) in premenopausal women.

Quality Assurance & Testing

Every peptide nasal spray we produce undergoes rigorous dual-verification testing before release. Our quality assurance protocol for PT-141 includes HPLC purity analysis (minimum 98% needed for release — our PT-141 consistently exceeds 99%), mass spectrometry molecular identity confirmation verifying the correct 1025.18 g/mol molecular weight and cyclic heptapeptide structure, visual appearance and solution clarity testing, pH testing for nasal compatibility, and sterility testing of the final spray form.
We publish batch-specific Certificates of Analysis with every order and keep a publicly accessible COA archive on our website. All analytical testing is performed by an independent, ISO 17025-accredited laboratory to ensure objectivity and accuracy — never just in-house quality control. Every COA includes the HPLC chromatogram, mass spectrum, and detailed impurity profile so you can verify our results against your own analytical standards.

Current Batch Data — PH-2026-NS087

• ✓ HPLC Purity: 99.4%
• ✓ Mass Spectrometry: Confirmed — MW 1025.18 g/mol (±0.02)
• ✓ Appearance: Clear, colorless solution
• ✓ pH: 5.5 (optimized for nasal mucosal compatibility)
• ✓ Spray Volume Consistency: CV <5% across 50 actuations
• ✓ Sterility: Pass (USP <71> method)
• ✓ Lab: Independent ISO 17025-accredited facility

For more data about our testing methodology, visit our About Us page or browse our complete Certificate of Analysis Archive. Researchers can also explore our full peptide catalog including BPC-157, TB-500, and other research peptides. For questions about peptides for libido research or melanocortin receptor studies, our Melanocortin Peptides Research Guide provides full background.

Why Buy PT-141 Nasal Spray from PrymaLab?

When you choose to buy PT-141 nasal spray from PrymaLab, you benefit from:

• ✓ Verified 99%+ Purity — Every PT-141 peptide nasal spray batch undergoes rigorous HPLC testing with third-party check
• ✓ Ready-to-Use Format — No mixing, no syringes, no sterile water needed
• ✓ Calibrated Metered Dosing — Consistent dose delivery with <5% variation across all actuations
• ✓ ISO 17025-Accredited Testing — Independent lab verification with batch-specific COA included
• ✓ Cold-Chain Integrity — All products maintained at optimal temperatures from manufacturing to delivery
• ✓ Fast US Shipping — Quick delivery with discreet packaging and temperature control
• ✓ Full Documentation — Certificate of Analysis, research guidelines, and full product specifications included
• ✓ Research Support — Expert guidance on protocols and dosing for research peptide studies
• ✓ Competitive Pricing — Premium quality bremelanotide nasal spray at fair market prices
• ✓ Proven Track Record — Work with the peptide supplier researchers trust for melanocortin research peptides

Add this premium PT-141 nasal spray to your cart now and experience the convenience of ready-to-use intranasal peptide delivery. Join the researchers who trust PrymaLab for their peptide research needs.

Research Disclaimer

This PT-141 peptide nasal spray is intended for laboratory research purposes only. Not for human consumption. Not for use in food, drugs, medical devices, or cosmetics. This product is not a drug, supplement, or food product and has not been evaluated by the FDA. Buyers must be 18 years or older. Please consult all applicable federal, state, and local regulations before buying and using this product. By buying, you agree that this product will be used solely for legitimate research purposes in compliance with all applicable laws.